The Federal Trade Commission has issued a modified final order settling charges related to Perrigo’s acquisition of Paddock Laboratories. The FTC alleged that the deal would have reduced the number of manufacturers for ammonium lactate cream and lotion, ciclopirox shampoo, and promethazine suppositories. These products are used for conditions such as dry skin and motion sickness. The acquisition would have also eliminated future competition for two generic testosterone gel products used as anti-inflammatories.
To resolve the FTC’s charges, Perrigo and Paddock agreed to sell the six generic drugs to Watson Pharmaceuticals.
Full content: FTC Press Release
Related content: 2025: Reverse-Payment Settlements Unleashed
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Elon Musk Leads $97.4 Billion Bid to Take Control of OpenAI
Feb 10, 2025 by
CPI
Nigerian Court Confirms Consumer Protection Commission’s Authority Over Telecom Sector
Feb 10, 2025 by
CPI
Microsoft Under French Antitrust Investigation Over Bing Practices
Feb 10, 2025 by
CPI
Hausfeld Grows Antitrust Litigation Team
Feb 10, 2025 by
CPI
Microsoft Seeks to Ease EU Antitrust Concerns With Office Pricing Adjustment
Feb 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon